License Amendment. A. Section 2.2(i) of the Agreement is hereby deleted in its entirety and replaced with the following:
License Amendment. 2.1 The parties agree that, in exchange for a payment of $4,232.74 and the forgiveness of the remaining promissory notes of $16,741.65 ($20,974.39 - $4,232.74) and all remaining accrued interest (approximately but not limited to $3,653.43) owed by GOLDEN HAND to REACH and subject to the terms and conditions of this Agreement, GOLDEN HAND agrees to convert the licence to a worldwide non-exclusive licence
License Amendment. Lilly's license in Section 5.1 and Section 5.2 shall be amended to include "make" Product without restriction. Generex shall transfer to Lilly all manufacturing documents, including, without limitation, standard operating procedures, manufacturing tickets, and quality control and assurance documentation for manufacture of Product and shall permit Lilly to have the right to reference the DMFs and, if necessary, utilize any information in the DMFs to manufacture, and obtain any regulatory approval to manufacture Product. 2.
License Amendment. 2.1 The parties agree that, in exchange for the payment by promissory note of $30,000 by WIZBANG to REACH and subject to the terms and conditions of this Agreement, the Licensing Agreement dated September 22, 2000 and amended October 31, 2001 will be converted as follows: (a) The Licence Agreement will be a amended to include a worldwide exclusive licence for the sale of REACH's 41 to 160 Megabits per second range Digital Data Recorder product line;
License Amendment. 2.1 The parties agree that, in exchange for the payment by promissory note of $5,000 by DDR to REACH and subject to the terms and conditions of this Agreement, REACH will not terminate the Licensing Agreement dated June 3, 1999 for failure to purchase $50,000 of the Reach Technologies Inc. licensed product line by January 30, 2001. 2.2 All other terms in the Licensing Agreement dated June 3, 1999 shall remain including but not limited to the commitment to purchase $100,000 of the Reach Technologies Inc. licensed product line by January 31, 2002, and a further $100,000 by January 31, 2003, to retain its license. If these minimum purchase levels are not achieved, REACH shall have the right to terminate this agreement, immediately and without penalty. 3.
License Amendment. 2.1 The parties agree that, in exchange for the payment by promissory note of $20,000 by WIZBANG to REACH and subject to the terms and conditions of this Agreement, the Licensing Agreement dated September 22, 2000 will be converted as follows: (a) The Licence Agreement will be a worldwide exclusive licence, except in the territories of Washington DC, Virginia, West Virginia, Maryland, Pennsylvania, New York, Connecticut, Massachusetts, Vermont, New Hampshire, Maine, Ohio, Kentucky and Tennessee were the license will be non exclusive (the "Nonexclusive Territories")); (b) WIZBANG will continue to purchase and resell the Digital Data Recorder licensed product line from REACH; and (c) WIZBANG will also have the right to arrange for customer purchase orders to be made out directly to REACH and to require REACH to invoice the customers directly and to remit the gross invoice receipts to Wizbang when received. In such cases WIZBANG is required to remit the wholesale purchase price back to REACH within 5 days of receipt of the invoice proceeds. Arrangement may be made with REACH for later payment of the wholesale purchase price if mutually agreed.
License Amendment. Pursuant to the Penn SRA, the License may be amended to include in the Penn Patent Rights listed in Exhibit A certain inventions or improvements conceived under the Penn SRA and related to the Penn Patent Rights in the Field of Use consistent with the terms of this Agreement upon execution of an amendment to this Agreement by the Parties.
License Amendment. Whereas, the Public Health Service (PHS), Department of Health and Human Services (DHHS) and Calypte Biomedical Corporation, Inc. (Licensee) entered into a license agreement (L-108-99/0) effective August 6, 1996 relating to U.S. Patents 4,520,113, 4,647,773, 4,652,599, 4,708,818 and 5,135,864 and corresponding international patents disclosing antibody tests for HIV-1 ("Agreement"); and
License Amendment. 2.1 The parties agree that, in exchange for the amendment of the Licensing Agreement dated June 3, 1999 from an exclusive to a nonexclusive licence and subject to the terms and conditions of this Agreement, REACH will
License Amendment. 2.1 The parties agree that, in exchange for the payment by promissory note of $5,000 by BERT to REACH and subject to the terms and conditions of txxx Agreement, REACH will add the territory of Arizona to the Licensing Agreement dated May 31, 2000 and agrees to replace appendix A to the Agreement dated May 31, 2000 with the attached new appendix A. 2.2 All other terms in the Licensing Agreement dated May 31, 2000 shall remain.
